Soluble human leukocyte antigen g molecule expression in allogeneic hematopoietic stem cell transplantation: Good predictor of acute graft-versus-host disease

Acta Haematologica

Volumn 130, Issue 3, 2013, Pages 160-168

  Liu, Hui ^a   Chen, Yinkui ^a   Xuan, Li ^a   Wu, Xiuli ^a   Zhang, Yu ^a   Fan, Zhiping ^a   Huang, Fen ^a   Zhang, Xian ^a   Jiang, Qianli ^a   Sun, Jing ^a   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Prediction; Soluble human leukocyte antigen G

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HLA G ANTIGEN; HLA G5 ANTIGEN; HLA G6 ANTIGEN; HLA G7 ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; SOLUBLE HLA G5 ANTIGEN; SOLUBLE HLA G6 ANTIGEN; SOLUBLE HLA G7 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MOLECULE; PREDICTOR VARIABLE; PRIORITY JOURNAL; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; FEMALE; GENE EXPRESSION REGULATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-G ANTIGENS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84878056154     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000350488     Document Type: Article

References (47)

1. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
2. Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB, Marmont AM, Masaoka T, Ramsay NK, Rimm AA, Speck B, Zwaan FE, Bortin MM: Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
3. Poire X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K: Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma 2009; 50: 85-91.
4. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC: Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45: 295-302.
5. Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ, Broady RC, Forrest DL, Hogge DE, Nantel SH, Power MM, Song KW, Sutherland HJ, Smith CA, Narayanan S, Young SS, Connors JM, Shepherd JD: Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 2012; 158: 174-185.
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
7. Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P, Ringden O: G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217-223.
8. Sun ZM, Liu HL, Geng LQ, Wang XB, Yao W, Liu X, Ding KY, Han YS, Yang HZ, Tang BL, Tong J, Zhu WB, Wang ZY: HLA-matched sibling transplantation with G-CSF mobilized PBSCs and BM decreases GVHD in adult patients with severe aplastic anemia. J Hematol Oncol 2010; 3: 51.
9. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
10. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM: Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941-3946.
11. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, Hansen JA: Relation of an interleukin-promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349: 2201-2210.
12. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringden O: Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26: 5728-5734.
13. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
14. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V, Weisdorf D, Confer DL: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
15. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG: Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graftversus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76: 1742-1749.
16. Middleton PG, Norden J, Cullup H, Cavet J, Jackson GH, Taylor PR, Dickinson AM: Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplant 2003; 32: 41-47.
17. Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, Fabiani JN, Dausset J, Carosella ED, Carpentier A: Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002; 105: 1949-1954.
18. Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N: Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 2003; 39: 587-594.
19. Rebmann V, Bartsch D, Wunsch A, Mollenbeck P, Golda T, Viebahn R, Grosse-Wilde H: Soluble total human leukocyte antigen class I and human leukocyte antigen-G molecules in kidney and kidney/pancreas transplantation. Hum Immunol 2009; 70: 995-999.
20. Le Maux A, Noel G, Birebent B, Grosset JM, Vu N, De Guibert S, Bernard M, Semana G, Amiot L: Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol 2008; 152: 50-56.
21. Lindemann M, Rebmann V, Ottinger HD, Schmolke K, Kreuzfelder E, Grosse-Wilde H: rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors. Exp Hematol 2004; 32: 1103-1109.
22. Lazana I, Zoudiari A, Kokkinou D, Themeli M, Liga M, Papadaki E, Papachristou D, Spyridonidis A: Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at GvHD sites. Haematologica 2012; 97: 1338-1347.
23. Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H: Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009; 15: 1376-1385.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Horwitz ME, Sullivan KM: Chronic graft-versus-host disease. Blood Rev 2006; 20: 15-27.
26. Akhter A, Faridi RM, Das V, Pandey A, Naik S, Agrawal S: In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage. Tissue Antigens 2012; 80: 126-135.
27. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR: Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997; 186: 289-298.
28. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED: Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003; 64: 1039-1044.
29. Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L: The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006; 55: 1214-1222.
30. Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N: Erythroblasts secrete the nonclassical HLAG molecule from primitive to definitive hematopoiesis. Blood 2004; 104: 3153-3160.
31. Houlihan JM, Biro PA, Harper HM, Jenkinson HJ, Holmes CH: The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. J Immunol 1995; 154: 5665-5674.
32. Ishitani A, Geraghty DE: Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 1992; 89: 3947-3951.
33. Kirszenbaum M, Moreau P, Gluckman E, Dausset J, Carosella E: An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci USA 1994; 91: 4209-4213.
34. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510-4515.
35. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H: Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005; 159: 155-164.
36. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R: Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol 2000; 164: 6426-6434.
37. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006; 8: 223-230.
38. Giannopoulos K, Dmoszynska A, Bojarska-Junak A, Schmitt M, Rolinski J: Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol 2008; 46: 457-460.
39. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Rolinski J, Dmoszynska A: The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). Leuk Res 2008; 32: 1815-1819.
40. Sebti Y, Le Friec G, Pangault C, Gros F, Drenou B, Guilloux V, Bernard M, Lamy T, Fauchet R, Amiot L: Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003; 64: 1093-1101.
41. Guo QY, Chen BG, Ruan YY, Lin A, Yan WH: HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia. Leuk Res 2011; 35: 1350-1354.
42. Li R, Cao XH, Liu C, Wu XL, Ling YW, Zhang Y, Feng R, Liu QF: Clinical implications of HLA-G protein expression in acute leukemia. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 2446-2448.
43. Du X, Wu XL, Li R, Zhang Y, Fan ZP, Yi ZS, Liu QF: Role of membrane-bound human leukocyte antigen G in inducing immune tolerance after allogeneic hematopoietic stem cell transplantation. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 2202-2203.
44. Brugiere O, Thabut G, Pretolani M, Krawice-Radanne I, Dill C, Herbreteau A, Poras I, Moreau P, Colombat M, Danel C, Dehoux M, Fournier M, Carosella ED, Rouas-Freiss N: Immunohistochemical study of HLA-G expression in lung transplant recipients. Am J Transplant 2009; 9: 1427-1438.
45. Torres MI, Luque J, Lorite P, Isla-Tejera B, Palomeque T, Aumente MD, Arizon J, Pena J: 14-Base pair polymorphism of human leukocyte antigen-G as genetic determinant in heart transplantation and cyclosporine therapy monitoring. Hum Immunol 2009; 70: 830-835.
46. Chang CC, Ferrone S: HLA-G in melanoma: can the current controversies be solved? Semin Cancer Biol 2003; 13: 361-369.
47. Sheshgiri R, Gustafsson F, Sheedy J, Rao V, Ross HJ, Delgado DH: Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. J Heart Lung Transplant 2009; 28: 1193-1197.